glp-1 multiple endocrine neoplasia receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Beyond glycemia: Comparing tirzepatide to

Chromium adds further value by assisting in maintaining healthy blood glucose levels and reducing cravings

You're just not going to be able to achieve that, which is why I would say to everyone listening to this, if you suspect you have a thyroid condition, your best, best efforts now to get with a provider, get it diagnosed and start reversing that because Hashimoto's can be reversed, not cured, but the autoimmune attack can be reversed

muciniphila levels, which is arguably the population most in need of metabolic improvement

[24] Schadendorf D, Haas N, Worm M, et al

95% CI 38.87 to 17.22

Orforglipron (Foundayo) is the first nonpeptide, oral, oncedaily GLP1 receptor agonist, marking a meaningful shift in GLP1 therapy